METHODS
We analyzed the records of 445 patients treated between September 2009 and January 2014 in a reference radiology service in Florianopolis -Santa Catarina State, Brazil. We included patients older than 40 years, with seven variables into account (age, DRE, PSA, prostate volume, PSA density, transrretal prostate ultrasound and ultrasound-guided prostate biopsy with at least 12 fragments). We excluded patients with associated diseases that could compromise the data analysis, those previously submitted to prostatic resection and those in use of 5-alpha-reductase inhibitors.
We then selected 412 patients for the analysis.
All patients underwent DRE performed by a member of the urology team, classified as normal or abnormal, the latter including prostate hardening, presence of nodulation or irregularities. After DRE, we performed the ultrasound-guided transrectal biopsy.
The device used was the Samsung UGEO H60 model USS-H60NF40/US. We measured the prostate in three dimensions and estimated the prostate volume using the modified formula for elongated ellipsoid (0.52 x [length(cm) x depth(cm) x height(cm)]). We checked suspicious areas for the presence of PC. We considered as highly suspicious the hypoechoic nodules and diffusely heterogeneous prostates. We calculated the PSA density by dividing the serum PSA the calculated prostate volume. All patients underwent transrectal prostate biopsy using an 18 gauge, 20cm biopsy needle. We obtained a minimum of 12 fragments from each patient, with harvesting of additional fragments should there be highly suspicious areas. The same pathology laboratory was in charge of examining the biopsy specimens for the presence of adenocarcinoma.
We organized and registered data in a Microsoft Office Excel 2007® database, with double entry.
We performed statistical analysis using the Statistical Package for Social Sciences (SPSS), version 16 When dividing the age groups, level of PSA and DRE according to biopsy result (positive and negative), was found statistical significance for all: p=0.005 for age; p<0.001 for PSA levels; and p<0.001 for DRE.
RESULTS
We divided the study population into PSA lower than 4.0ng/ml, between 4.0 and 10 ng/ml, and greater than 10.0ng/ml, and classified them as for the presence or absence of PC ( Table 2) .
Sonographic Findings
We observed lesions suggestive of prostate cancer in 20.6% of patients. The median prostate volume was 45.15cm 3 . The median PSA density was 0.15ng/ml/cm 3 (Table 1) . When dividing these variables into positive and negative biopsy groups, we found statistical significance for all, with p<0.001.
Biopsy Results
We obtained a minimum of 12 specimens from all patients during the procedure. Prostate adenocarcinoma was identified in 37.62% (155 of 412 patients - Table 1 ).
Development of Predictive Model
For the univariate logistic regression, the significant predictors for a positive biopsy were: age, with odds ratio (OR) of 1.04 (p=0.005); prostate volume, OR 0.96 (p<0.001); altered DRE, OR 1.51 (p<0.001); ultrasound suggestive of cancer, OR 6.2 (p<0.001); PSA levels between 4-10 ng/ml, OR 2.25 (p=0.007); and PSA value ≥10.0ng/ml, with OR 4.80 (p=0.007). We did not observe statistical significance for the variable PSA density: OR 1.53 (p=0.314 - Table 3 ).
The multivariate logistic regression appointed as significant predictors for the presence of prostate carcinoma: age (p=0.017); prostate volume (p<0.001); altered DRE (p<0.001); ultrasound suggestive of cancer (p<0.001); and PSA (p=0.012) ( Table 3 ).
With the data obtained, we built a ROC curve with all model variables to evaluate the accuracy compared with PSA and DRE alone ( 
DISCUSSION
The screening for prostate cancer based on PSA and DRE still has important limitations, since the PSA is highly sensitive, but it is not cancer-specific and tumors. This indicates that the PSA should not be considered as the only factor in choosing patients for prostate biopsy 15 . The findings of this study corroborate this, since approximately 20% of patients with PSA less than 4.0ng/ml had PC diagnosis ( Table 2) .
Because of these limitations, statistical models began to be developed to more accurately predict the risk of PC in the biopsy. Eastham et al. 16 published, in 1999, the first study demonstrating a model that included age, ethnicity and PSA. Only PSA was an independent predictor of positive biopsy in their analysis, with an area under the curve of 0.75. However, the study was conducted during the period in which the default was the harvesting of six prostate fragments.
This may limit the analysis results, as this pattern has less sensitivity to the currently used twelve fragments 17 This study evaluated, within the same population, the best combination of variables to be used for PC prediction and then created models that meet these characteristics. We saw that the most ROC curve of 0.86 for predicting the risk of PC. The results obtained are consistent with those obtained in other studies 1, 10, 16, 20 . Most of the published studies have been limited to PSA values less than 10.0ng/ml, with the justification that any patient with values above that would be subjected to a prostate biopsy 10, 11, 16 . In this study, we chose not to limit the PSA, as there was a rate of nearly 50% negative biopsies in this population subgroup, which would open room for a better patient's selection for biopsy including these PSA values.
It would be a new paradigm that needs further study and deepening, but would have the main benefit of avoiding repeated biopsies in such patients.
Some limitations are present in the model presented in this study. First, it we did not take into account the possible outcome of a repeated biopsy for those with negative findings on an initial biopsy, taking into consideration that false negatives may occur 21 . Second, we collected secondary character data retrospectively, and thus, their records were not designed and completed to meet the research objectives. Finally, the proposed model has not been validated externally. This can cause it to present different results in other populations. This raises the need for other research centers to confirm and validate the results of any predictive model in use [22] [23] [24] .
The results indicate that the clinical, laboratory and ultrasound information, besides easily obtained in clinical practice, can better stratify the risk of patients undergoing prostate biopsy. Objetivo: desenvolver um modelo preditivo para estimar a probabilidade de câncer prostático previamente à biópsia. Métodos: de setembro de 2009 até janeiro de 2014, 445 homens foram submetidos à biópsia prostática em um serviço de radiologia. Pacientes com doenças que pudessem comprometer a análise de dados, submetidos à ressecção prostática ou usando inibidores de 5-alfa-redutase foram excluídos do estudo. Dessa forma, 412 pacientes foram selecionados. Variáveis incluídas no modelo foram idade, antígeno prostático específico (PSA), toque retal, volume prostático e achados ultrassonográficos anormais. Curvas de Características Operacionais (ROC) foram construídas e áreas sob a curva foram calculadas, assim como os Valores Preditivos Positivos (VPP) do modelo. Resultados: dos 412 homens, 155 (37,62%) tinham câncer de próstata (CAP). A média da idade foi 63,8 anos, a mediana do PSA foi 7,22ng/ml. Além disso, 21,6% e 20,6% dos pacientes apresentou anormalidades no toque retal e imagem sugestiva de câncer pela ultrassonografia, respectivamente. A mediana do volume prostático e da densidade do PSA foram 45,15cm 3 e 0,15ng/ml/cm 3 , respectivamente. Análises univariada e multivariada demonstraram que apenas cinco fatores de risco estudados são preditores de CAP no estudo (p<0,05). A densidade de PSA foi excluída do modelo (p=0,314). A área sob a curva ROC para predição de CAP foi 0,86. O VPP foi 48,08% para sensibilidade de 95% e 52,37% para sensibilidade de 90%. Conclusão: Os resultados indicam que informações clínicas, laboratoriais e ultrassonográficas, além de serem facilmente obtidas, podem estratificar melhor o risco de pacientes que serão submetidos à biópsia prostática.
Descritores: Neoplasias da Próstata. Biópsia. Antígeno Prostático Específico.
R E S U M O

